Redeye provides an update following Optomed’s FDA clearance for Aurora AEYE and the company’s Q1 report. The report fairly aligned with our expectations; however, slightly lower sales than expected. Moreover, we argue that the FDA clearance is a major milestone for the company and that upcoming US subscriptions could generate a significant part of future sales. We make some changes to our US sales approach assumptions, rendering an updated fair value range.